Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Reporting results of cancer treatment

1981 • 7,916 citations

Prostate-specific membrane antigen expression in normal and malignant human tissues.

1997 • 1,454 citations

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1996 • 613 citations

Expression of the prostate-specific membrane antigen.

1994 • 582 citations

Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.

1997 • 509 citations

Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

1998 • 419 citations

Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.

1996 • 380 citations

Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids

1995 • 362 citations

Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase.

1996 • 360 citations

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

1996 • 336 citations

Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma

2003 • 295 citations

Targeting Metastatic Prostate Cancer With Radiolabeled Monoclonal Antibody J591 to the Extracellular Domain of Prostate Specific Membrane Antigen

2003 • 251 citations

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.

2000 • 206 citations

( ¹¹¹ ) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY

1998 • 177 citations

Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.

1990 • 136 citations

Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody.

1996 • 132 citations

ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients.

1998 • 111 citations

Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen

1995 • 104 citations

Indium-111 Capromab Pendetide (ProstaScint) Imaging to Detect Recurrent and Metastatic Prostate Cancer

1998 • 88 citations

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

2000 • 88 citations

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and ⁹⁰yttrium‐DOTA‐peptide‐ChL6

2001 • 69 citations

High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

2000 • 68 citations

Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice

2003 • 67 citations

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone

2002 • 58 citations

A Phase II Study of [⁹⁰Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy

1999 • 55 citations

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

2001 • 53 citations

The clinical role of prostate-specific membrane antigen (PSMA)

2002 • 44 citations

Imaging and phase I study of 111In- and 90Y-labeled anti-LewisY monoclonal antibody B3.

2000 • 37 citations